N/A
Completed N=39
A Study to Evaluate Nicotine Uptake and Biomarkers in Adult Smokers Using mybluTM Electronic Cigarettes
Healthy Volunteers
Source: ClinicalTrials.gov NCT04429932 ↗
Enrolled (actual)
39
Serious AEs
0.0%
Results posted
Jun 2021
Primary outcomePrimary: Maximum Nicotine Concentration in Blood — 6.6; 7.9; 5.6; 6.0 ng/mL
Summary
This study evaluates the overall performance of the currently-marketed MybluTM e-cigarette device and pods, as assessed by nicotine uptake, exposure to smoke constituents, safety and consumer satisfaction, over 8 days. The study is designed as an open-label, randomized study in adult smokers.
Subjects are invited to participate to a second part of the study, for 5 additional days, to compare the use of MybluTM to the use of subject's usual brand combustible cigarettes.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Maximum Nicotine Concentration in Blood |
6.6; 7.9; 5.6; 6.0; 2.6; 2.7 | — |
| PRIMARY Concentration of Carboxyhemoglobin in Blood |
5.4; -4.0 | — |
| PRIMARY Amount of 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol in Urine in 24 Hours |
176.2; -134.8 | — |
| PRIMARY Amount of 3-hydroxypropylmercapturic Acid in Urine in 24 Hours |
756.2; -599.3 | — |
| PRIMARY Amount of S-phenyl Mercapturic Acid in Urine in 24 Hours |
2.6; -2.5 | — |
| SECONDARY Level of White Blood Cells |
6.9; -0.6 | — |
| SECONDARY Spirometry: Forced Expiratory Volume in 1 Second |
98.0; 98.6 | — |
| SECONDARY Spirometry: Forced Vital Capacity |
101.0; 100.3 | — |
| SECONDARY Subjective Measure: Urge to Smoke |
72.3; 76.4; 64.9; 67.6; 53.7; 54.4 | — |
Eligibility Criteria
Inclusion Criteria
- smoking an average of at least 10 manufactured combustible cigarettes per day for at least 12 months prior to Screening
- tested positive for urine cotinine (≥ 200 ng/mL) at Screening
- exhaled carbon monoxide > 10 ppm (parts per million) at Screening
Exclusion Criteria
- relevant illness history
- relevant medication use
- body mass index (BMI) > 40 kg/m2 or < 18 kg/m2 at Screening
- allergy to propylene glycol or glycerin
- use of nicotine-containing products other than manufactured combustible cigarettes within 14 days prior to Check-in
- use of any prescription smoking cessation treatments within 3 months prior to Check-in
- smokers who draw smoke from the cigarette into the mouth and throat but do not inhale
- planning to quit smoking during the study
- female subjects who are pregnant, lactating, or intend to become pregnant
Data sourced from ClinicalTrials.gov (NCT04429932). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.